In combination with the presence of SETD2-inactivating mutations in a substantial proportion of ccRCC, this clearly demonstrates SETD2′s role as a suppressor of both tumor initiation and progression. The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.